Format Double-blinded multi-center RCT
Treatment Fondaparinux 2.5mg daily
Control Enoxaparin 1mg/kg
Population 20,078 patients
Inclusion criteria Patients were randomly assigned to a study group within 24 hours after the onset of symptoms and were eligible if they met at least two of the three following criteria: an age of at least 60 years, an elevated level of troponin or creatine kinase MB isoenzyme, or electrocardiographic changes indicative of ischemia.
Exclusion criteria Contraindications to low-molecular-weight heparin
Recent hemorrhagic stroke
Indications for anticoagulation other than an acute coronary syndrome
Serum creatinine level of at least 3 mg per deciliter (265 Î_mol per liter)
Follow-up Minimum 90d, max 180d
Primary endpoint Death, myocardial infarction, or refractory ischemia

Primary safety objective was to determine whether fondaparinux was superior to enoxaparin in preventing major bleeding.
Secondary endpoint(s) Death or myocardial infarction
Death, myocardial infarction, or refractory ischemia
The individual components of these composite outcomes

...At 30 days and at the end of the study
Details .
Brief summary: Fondaparinux in UA/NSTEMI less bleeding than enoxaparin hence improved mortality
PAPER: Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes
Date 6 Apr 2006
Journal N Engl J Med. 2006 Apr 6;354(14):1464-76.
Information Fondaparinux 2.5mg vs Enoxaparin 1mg/kg
-Similar risks of ischaemic events @ 9days
-Significant reduction (50%) in major bleeding
-Significant improvement in long-term mortality (17%) & morbidity
PAPER: Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Date 30 Oct 2007
Journal J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51.
Information Subgroup analysis on patients undergoing PCI
Fondparinux 2.5mg vs Enoxaparin 1mg/kg
-Reduced risks of major bleeding
-Catheter thrombus more common in patients receiving fondaparinux
--Largely prevented by using unfractionated heparin @ PCI (no increase in bleeding)